This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rifai, A. Articles by Schlingensiepen, K. H. Search for Related Content PubMed PubMed Citation Articles by Rifai, A. Articles by Schlingensiepen, K. H.

American Journal of Pathology, Vol 149, 717-725, Copyright © 1996 by American Society for Investigative Pathology

REGULAR ARTICLES

Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice

A Rifai, W Brysch, K Fadden, J Clark and KH Schlingensiepen
Department of Pathology, Rhode Island Hospital, Brown University School of Medicine, Providence 02903, USA.

We examined the dynamics of removal from circulation, tissue distribution, and persistence of phosphorothioate oligodeoxynucleotides (S-ODN) anti-tumor-necrosis-factor and a control of random sequence (randomer) in mice. After intravenous injection, the majority (96%) of S-ODN cleared rapidly from the circulation in the first two phases. In the first phase, 37.8 +/- 2.3% of the radioactivity had a mean half- life (t1/2) of 2.0 +/- 0.4 minutes. In the second phase, 58.1 +/- 1.5% of the radioactivity cleared with t1/2 of 12.6 +/- 0.2 minutes. The catabolic phase, constituting a minor proportion (4.1 +/- 0.8% of the total radioactivity), had a mean t1/2 of 2.7 +/- 0.5 hours. At a low dose (1 microgram) tissue distribution of both S-ODN anti-tumor- necrosis-factor and randomer were similar. The liver and kidneys were the major organs involved in uptake and removal of S-ODN. Autoradiographic studies showed the liver Kupffer cells to be the major site of uptake and renal urinary space for elimination. The clearance rate from the circulation was increased with the dose of S-ODN. In contrast, the fraction of radioactivity localized in the kidneys, liver, and spleen was decreased with increase in dosage. Furthermore, at a high dose (200 micrograms), the tissue distribution of the S-ODN anti-tumor-necrosis-factor differed significantly from the randomer. These findings have general significance in showing that the liver and kidneys are the major organs for removal of S-ODN and these organs are saturable at high doses. In addition, the results have specific importance in defining different parameters, dose and base composition, that affect utilization of antisense oligonucleotides for controlling gene expression in vivo.

This article has been cited by other articles:

				N. Tran, A. Koch, R. Berkels, O. Boehm, P. A. Zacharowski, G. Baumgarten, P. Knuefermann, M. Schott, W. Kanczkowski, S. R. Bornstein, et al. Toll-Like Receptor 9 Expression in Murine and Human Adrenal Glands and Possible Implications during Inflammation J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2773 - 2783. [Abstract] [Full Text] [PDF]

				F. M. van de Water, O. C. Boerman, A. C. Wouterse, J. G. P. Peters, F. G. M. Russel, and R. Masereeuw INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES Drug Metab. Dispos., August 1, 2006; 34(8): 1393 - 1397. [Abstract] [Full Text] [PDF]

				R. S. Geary, R. Z. Yu, T. Watanabe, S. P. Henry, G. E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A. A. Levin PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-{alpha} PHOSPHOROTHIOATE 2'-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES Drug Metab. Dispos., November 1, 2003; 31(11): 1419 - 1428. [Abstract] [Full Text] [PDF]

				S. P. Ho, M. S. Scully, C. M. Krauthauser, E. J. Wexler, M. D. Stow, J. E. Dinchuk, J. S. Kerr, and P. A. Friedman Antisense Oligonucleotides Selectively Regulate Aspartyl beta -Hydroxylase and Its Truncated Protein Isoform in Vitro but Distribute Poorly into A549 Tumors in Vivo J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 795 - 803. [Abstract] [Full Text] [PDF]

				R. M. Crooke, M. J. Graham, M. J. Martin, K. M. Lemonidis, T. Wyrzykiewiecz, and L. L. Cummins Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 140 - 149. [Abstract] [Full Text]

				M. J. Graham, S. T. Crooke, D. K. Monteith, S. R. Cooper, K. M. Lemonidis, K. K. Stecker, M. J. Martin, and R. M. Crooke In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 447 - 458. [Abstract] [Full Text]

				E. A. L. Biessen, H. Vietsch, J. Kuiper, M. K. Bijsterbosch, and T. J. C. v. Berkel Liver Uptake of Phosphodiester Oligodeoxynucleotides Is Mediated by Scavenger Receptors Mol. Pharmacol., February 1, 1998; 53(2): 262 - 269. [Abstract] [Full Text]

				R. S. Geary, J. M. Leeds, J. Fitchett, T. Burckin, L. Truong, C. Spainhour, M. Creek, and A. A. Levin Pharmacokinetics and Metabolism in Mice of a Phosphorothioate Oligonucleotide Antisense Inhibitor of C-raf-1 Kinase Expression Drug Metab. Dispos., November 1, 1997; 25(11): 1272 - 1281. [Abstract] [Full Text]

				J. M. Glover, J. M. Leeds, T. G. K. Mant, D. Amin, D. L. Kisner, J. E. Zuckerman, R. S. Geary, A. A. Levin, and W. R. Shanahan Jr. Phase I Safety and Pharmacokinetic Profile of an Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS 2302) J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1173 - 1180. [Abstract] [Full Text]